Companies developing RNA-editing therapies are rallying Wednesday after breakthrough data from a clinical trial showed the technology’s promise as a treatment. Wave Life Sciences Ltd. said it achieved ...
WAVE Life Sciences (NASDAQ:WVE) executives used the company’s fourth-quarter and full-year 2025 earnings call to highlight ...
Wave Life Sciences (WVE) was not the only developer of RNA editing therapies to show significant stock gains from its historic proof-of-mechanism for its RNA editing platform, shown recently in the ...
ProQR Therapeutics advances RNA editing pipeline with upcoming CTA filing for AX-0810, while enhancing leadership and maintaining strong finances. ProQR Therapeutics N.V. announced significant ...
A research team has uncovered new insights into the molecular mechanisms of ADAR1, a protein that regulates ribonucleic acid (RNA) induced immune responses. Their findings could open new pathways for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results